Swine Flu Vaccine Market

Global Swine Flu Vaccine Market is valued at USD 9.84 Billion in 2017 and it is expected to reach USD 17.26 Billion by 2027 with a CAGR of 5.78% over the forecast period.

 Global Swine Flu Vaccine Market: Global Size, Trends, Competitive, Historical & Forecast Analysis To 2021-2027,Innovations in vaccine manufacturing, increasing incidence of epidemic swine flu and rising awareness for precaution against swine flu has anticipated the growth of the global swine flu vaccine market.

 Scope of Global Swine Flu Vaccine Market Report-

Swine flu is the type of respiratory disease caused by type A virus on pigs which is mainly caused by the H1N1 virus and can transmit to humans as well. This flu is the combination of the bird, swine and human flu virus and new strain of H1N1 which further combined with a Eurasian pig flu virus which leads to the term swine flu. The strains of swine flu are H1N1 flu virus, H1N2 virus, and H3N2 virus. Symptoms of swine flu in pigs are high fevers, going off feed, breathing difficulties, barking, and sneezing. Some cases have also reported with the neurological problems, vomiting and diarrhea etc., At present pigs and human share the same flu H1N1 pandemic virus. Diagnosis of H1N1 virus can be done through oropharyngeal tissue swab or nasopharyngeal from the patient. The world health organization declared that H1N1 virus was reported in 2009 and the first few cases were found in the U.S.

 COVID-19 pandemic has shown the negative impact on the global swine flu vaccine market; this is due to the shortage of labor or worker as compared to pre-covid in manufacturing units, the lockdown also restricted the transport & travel from one region to another along with unavailability of raw material. Along with this, the manufacturing units were shut down which hampered the production due to the strict government regulations. As most of the key players were focusing on corona virus pandemic, which lead to the low production in the swine flu vaccines. According to the world-o-meter, the confirmed cases of corona virus are 262,505,478 and out of which around 5,227,127 died.

 Global Swine Flu Vaccine Market Segmentation: -

Global swine flu vaccine market is segmented on the basis of vaccine type, brand, end user, and region and country level. Based on the vaccine type the global swine flu vaccine market is classified into intranasal, toxoid, conjugate, inactivated vaccine, attenuated vaccine and others. Based on the brand the global swine flu vaccine market is classified into influgen, agripal, nasovac, fiuarix, vaxigrip and others. Based on the end user the global swine flu vaccine market is classified into hospitals, clinics, and others.

 By Vaccine Type:

• Intranasal
• Toxoid
• Conjugate
• Inactivated Vaccine
• Attenuated Vaccine
• Others

By Brand:

• Influgen
• Agripal
• Nasovac
• Fiuarix
• Vaxigrip
• Others

By End User:

• Hospital
• Clinic
• Others

Key Players for Global Swine Flu Vaccine Market Report-

Some major key players for global swine flu vaccine market report cover prominent players like

• Sanofi Pasteur,
• GlaxoSmithKline,
• Panacea Biotec Ltd.,
• AstraZeneca plc.
• Baxter,
• Zydus Cadila,
• Johnson & Johnson Services,
• Cipla Inc.
• others

News:

Swine flu vaccination in pregnant women did not increase risk of autism in offspring

August 31, 2020: American Association for the Advancement of Science has conducted the research to rule out the risk of autism in offspring caused due to swine flu vaccination in pregnant women. The study consists of 39,726 vaccine-exposed children, 394 (cumulative incidence, 1.0%) had a diagnosis of autism-spectrum disorder during the six-year follow-up compared with 330 (1.1%) among 29,293 unexposed children. Adjusting for potential confounders, H1N1 vaccine exposure during fetal life was not associated with a later childhood diagnosis of autism-spectrum disorder.

 Innovation in vaccine manufacturing, increasing incidence of epidemic and rising awareness about precautions against swine flu followed by declining immunity and rising geriatric population has boosted the growth of global swine flu market.

 One of the major driving factors that boost the global swine flu vaccines market is innovation in vaccine manufacturing and rising awareness in people due to the increasing incidence of swine flu. The innovation in manufacturing of vaccine is universally accepted and will be used to develop awareness of H1N1 influenza. According to CDC, almost 1, 51,700-5, 75,400 people died due to the H1N1 virus during the first year of virus discovery. Another factor that drives the market growth is declining immunity among geriatric population. Rising geriatric population with weaken immune systems makes them susceptible to swine flu infection at a higher rate. H1N1 flu can affect anyone, but immunocompromised people such as cancer patients are more susceptible to swine flu and other infections. It is also found that epitopes on H1N1 are found in seasonal flu and will circulate for years. According to un.org, the population above age 65 years constitutes of 703 million in 2019 and will reach its double approximately 1.5 billion by 2050 world-wide. However, factors that restrain the market growth are stringent rules and regulation of government, high production cost to implement production to meet the population targets. On the other hand, increase in investments and R&D led to development of innovative and effective swine flu vaccine in near future and can create ample opportunities. 

North America is set to maintain its Dominance in Global Swine Flu Market.

North America is expected to dominate the global swine flu vaccine market due to its vaccine manufacturing technologies and developed infrastructure in this region including the presence of key players. Four swine flu vaccine manufacturers received an approval from FDA, for the use of monovalent influenza vaccine in the prevention of H1N1 virus. The four manufacturers are Sanofi Pasteur, CSL limited, Medimmune LLC, and Novartis vaccines and diagnostics limited. According to the clinicaltrailsarena.com, Sanofi received an order of USD 190 million from US department for producing bulk vaccines to curb the spread of disease. Also, Sanofi signed an agreement for the supply and production of vaccine with Butantan Institute, a Brazilian biomedical research Centre which includes to supply 18 million doses of vaccines of swine flu. 

Another factor driving the growth of swine flu vaccine market is developed healthcare infrastructure in North America region. Infrastructure is the key pillar for supporting the aim of promoting high standards of care and wellbeing of patients. According to the U.S. bureau of labor, the population of United States is around 328.2 million in 2019 and number of hospitals are 13,944 which give the ratio of approximate 23,540 person per hospital.

 On the other hand, Asia Pacific is expected to develop at a significant rate during the forecast period owing to the government initiatives to control the spreading of swine flu virus and rising awareness among people to prevent from disease. Governments are taking different initiatives to avoid spreading of diseases in people through various programs, vaccination campaigns and testing kits which is contributing the growth of swine flu vaccine market. According to the economics time, Maharashtra (India) government has procured around 1.29 lakhs swine flu vaccine doses for free vaccination. Thus all the above mentioned factors are likely to fuel the growth of swine flu vaccine market over the forecast period.

 The regions covered in this global swine flu vaccines market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East, GCC (UAE, Saudi Arabia, Kuwait) Africa, etc.

 On Special Requirement Global Swine Flu Vaccine Market Report is also available for below Regions and Country:

North America

• U.S.
• Canada

Europe 

• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Switzerland
• Belgium
• Rest of Europe

Asia-Pacific

• South Korea
• Japan
• China
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Colombia
• Brazil
• Argentina
• Peru
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Report Analysis	Details
Historical data	2015 - 2020
Forecast Period	2021 - 2027
Market Size in 2017:	USD 9.84 Billion
Base year considered	2020
Forecast Period CAGR %:	5.78%
Market Size Expected in 2027:	USD 17.26 Billion
Tables, Charts & Figures:	175
Pages	200
Key Players/Companies	Sanofi Pasteur, GlaxoSmithKline, Panacea Biotec Ltd., AstraZeneca plc. Baxter, Zydus Cadila, Johnson & Johnson Services, Cipla Inc. others
Segments Covered	By Vaccine Type, By Brand, By End User.
Regional Analysis	North America, U.S., Canada, , Europe, Germany, France, U.K., Italy, Spain, Sweden, Netherland, Turkey, Switzerland, Belgium, Rest of Europe, Asia-Pacific, South Korea, Japan, China, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest Of APAC, Latin America, Mexico, Colombia, Brazil, Argentina, Peru, Rest of South America, Middle East and Africa, Saudi Arabia, UAE, Egypt, South Africa, Rest Of MEA

 

Key Benefits for Global H1N1 Vaccines Market Report–

• Global H1N1 Vaccines Market report covers in-depth historical and forecast analysis.
• Global H1N1 Vaccines Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
• Global H1N1 Vaccines Market report helps to identify opportunities in marketplace.
• Global H1N1 Vaccines Market report covers extensive analysis of emerging trends and competitive landscape.